FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023405922> ?p ?o ?g. }

• W2023405922 abstract "Background: The outcome for children and adolescents with BL has improved significantly but for patients who relapse or progress, the prognosis is dismal due to chemo-immuno-radiotherapy resistance (Cairo, et al, J Clin Oncol, 2012). Novel, non-chemotherapy-based therapies are desperately needed for this specific poor risk population. Czuczman et al generated Rituximab resistant BL cell lines, which provided a good model to study mAb resistance and design novel therapies (Czuczman et al, Clinical Cancer Research, 2008). Natural Killer (NK) cells play an important role in tumor surveillance post allogeneic stem cell transplantation (Ruggeri L et al., Science 2002) but cell number and tumor specific recognition limit adoptive NK cell therapy (Shereck/Cairo, PBC 2007). Efficient expansion of primary NK cells with K562-mbIL15-41BBL and retargeting expanded NK cells with Anti-CD20 CAR by retrovirus were reported by our group previously (Chu & Cairo, et al, ASH, 2011). Objective: To generate large-scale, efficiently modified NK cells with low cost, clinical applicable and a non-viral method and to apply these modified NK cells on antibody resistant BL, we investigated the functional activities of anti-CD20 chimeric antigen receptor (CAR+) modified PBNK cells following mRNA nucleofection against rituximab resistant BL cells. Methods: PBMC were expanded with inactivated K562-mbIL15-41BBL cells for 7 or 14 days. CD56+CD3- expanded PBNK (exPBNK) cells were isolated using NK cell isolation kit. CD56, CD3 and receptor expression were evaluated by flow cytometry. Anti-CD20-4-1BB-CD3ζ mRNA (CAR mRNA) was produced using the mMESSAGE mMACHINE T7 Ultra kit. CAR mRNA was nucleofected into exPBNK using Amaxa nucleofector. CAR expression was detected using FITC-conjugated goat anti-mouse IgG, F(ab9)2 fragment-specific antibody. exPBNK cytotoxicity was assessed by europium release assay against CD20+ Ramos, Daudi, Raji, two Rituximab resistant cell lines: Raji-2R and Raji-4RH, and CD20- control cells: RS4;11 and Jurkat. CD107a degranulation in exPBNK was measured by flow cytometry. Results: CD56+CD3- exPBNK cells were significantly expanded by mitomycin C treated K562-mbIL15-41BBL cells at day7. exPBNK cells were selected with more than 96% purity of CD56+CD3-. 50 to 95% exPBNK cells were detected to express CAR at 16 hrs after CAR mRNA nucleofection. CAR mRNA nucleofection did not affect the expression of exPBNK activating receptors or inhibitory receptors. exPBNK in vitro cytotoxicity was significantly enhanced by CAR+ exPBNK compared to CAR- exPBNK against CD20+ BL at E:T=10:1 (n>3, p Consistently, CD107a degranulation was enhanced in CAR+ exPBNK compared to CAR- exPBNK in response to CD20+ Ramos, however, there was no significant difference in response to RS4;11 or medium. Conclusion: Anti-CD20 CAR expression in exPBNK cells results in significant and specific exPBNK in vitro cytotoxicity against CD20+ BL and Rituximab resistant cell lines associated with a significant increase in CD107 degradulation. Future directions include examining CAR+ exPBNK cytotoxic activity against CD20+ resistant tumor cells from patients and testing the anti-tumor activity of CAR+ exPBNK against resistant cells in xenograft mice. Citation Format: Yaya Chu, Janet Ayello, Ashlin Yahr, Jared Katz, Lowrence Lo, Allyson Flowers, Mitchell S. Cairo. Significantly targeting rituximab resistant B-cell lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr A19." @default.
• W2023405922 created "2016-06-24" @default.
• W2023405922 creator A5001697191 @default.
• W2023405922 creator A5012947331 @default.
• W2023405922 creator A5017266140 @default.
• W2023405922 creator A5049914171 @default.
• W2023405922 creator A5054300233 @default.
• W2023405922 creator A5060002714 @default.
• W2023405922 creator A5061246385 @default.
• W2023405922 date "2013-01-01" @default.
• W2023405922 modified "2023-09-25" @default.
• W2023405922 title "Abstract A19: Significantly targeting rituximab resistant B-cell lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells." @default.
• W2023405922 doi "https://doi.org/10.1158/1538-7445.tumimm2012-a19" @default.
• W2023405922 hasPublicationYear "2013" @default.
• W2023405922 type Work @default.
• W2023405922 sameAs 2023405922 @default.
• W2023405922 citedByCount "0" @default.
• W2023405922 crossrefType "proceedings-article" @default.
• W2023405922 hasAuthorship W2023405922A5001697191 @default.
• W2023405922 hasAuthorship W2023405922A5012947331 @default.
• W2023405922 hasAuthorship W2023405922A5017266140 @default.
• W2023405922 hasAuthorship W2023405922A5049914171 @default.
• W2023405922 hasAuthorship W2023405922A5054300233 @default.
• W2023405922 hasAuthorship W2023405922A5060002714 @default.
• W2023405922 hasAuthorship W2023405922A5061246385 @default.
• W2023405922 hasConcept C129374314 @default.
• W2023405922 hasConcept C147483822 @default.
• W2023405922 hasConcept C159654299 @default.
• W2023405922 hasConcept C167672396 @default.
• W2023405922 hasConcept C18031839 @default.
• W2023405922 hasConcept C203014093 @default.
• W2023405922 hasConcept C2777701055 @default.
• W2023405922 hasConcept C2780653079 @default.
• W2023405922 hasConcept C3875195 @default.
• W2023405922 hasConcept C502942594 @default.
• W2023405922 hasConcept C71924100 @default.
• W2023405922 hasConcept C8891405 @default.
• W2023405922 hasConceptScore W2023405922C129374314 @default.
• W2023405922 hasConceptScore W2023405922C147483822 @default.
• W2023405922 hasConceptScore W2023405922C159654299 @default.
• W2023405922 hasConceptScore W2023405922C167672396 @default.
• W2023405922 hasConceptScore W2023405922C18031839 @default.
• W2023405922 hasConceptScore W2023405922C203014093 @default.
• W2023405922 hasConceptScore W2023405922C2777701055 @default.
• W2023405922 hasConceptScore W2023405922C2780653079 @default.
• W2023405922 hasConceptScore W2023405922C3875195 @default.
• W2023405922 hasConceptScore W2023405922C502942594 @default.
• W2023405922 hasConceptScore W2023405922C71924100 @default.
• W2023405922 hasConceptScore W2023405922C8891405 @default.
• W2023405922 hasLocation W20234059221 @default.
• W2023405922 hasOpenAccess W2023405922 @default.
• W2023405922 hasPrimaryLocation W20234059221 @default.
• W2023405922 hasRelatedWork W2027053879 @default.
• W2023405922 hasRelatedWork W2030204783 @default.
• W2023405922 hasRelatedWork W2127169662 @default.
• W2023405922 hasRelatedWork W2324434844 @default.
• W2023405922 hasRelatedWork W2541758428 @default.
• W2023405922 hasRelatedWork W2561085742 @default.
• W2023405922 hasRelatedWork W2562013484 @default.
• W2023405922 hasRelatedWork W2574268995 @default.
• W2023405922 hasRelatedWork W2581749833 @default.
• W2023405922 hasRelatedWork W2588546701 @default.
• W2023405922 hasRelatedWork W2596787906 @default.
• W2023405922 hasRelatedWork W2901742648 @default.
• W2023405922 hasRelatedWork W2911999245 @default.
• W2023405922 hasRelatedWork W2913279485 @default.
• W2023405922 hasRelatedWork W2944248975 @default.
• W2023405922 hasRelatedWork W2946233185 @default.
• W2023405922 hasRelatedWork W3096532113 @default.
• W2023405922 hasRelatedWork W3140414879 @default.
• W2023405922 hasRelatedWork W3180031061 @default.
• W2023405922 hasRelatedWork W2098562115 @default.
• W2023405922 isParatext "false" @default.
• W2023405922 isRetracted "false" @default.
• W2023405922 magId "2023405922" @default.
• W2023405922 workType "article" @default.